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ABSTRACT
High levels of expression of glycoprotein non-metastatic B (gpNMB) in triple
negative breast cancer (TNBC) and its association with metastasis and recurrence make
it an attractive target for therapy with the antibody drug conjugate, glembatumumab
vedotin (CDX-011). This report describes the development of a companion PET-based
diagnostic imaging agent using 89Zr-labeled glembatumumab ([89Zr]DFO-CR011) to
potentially aid in the selection of patients most likely to respond to targeted treatment
with CDX-011. [89Zr]DFO-CR011 was characterized for its pharmacologic properties in
TNBC cell lines. Preclinical studies determined that [89Zr]DFO-CR011 binds specifically
to gpNMB with high affinity (Kd = 25 ± 5 nM), immunoreactivity of 2.2-fold less than
the native CR011, and its cellular uptake correlates with gpNMB expression (r = 0.95).
In PET studies at the optimal imaging timepoint of 7 days p.i., the [89Zr]DFO-CR011
tumor uptake in gpNMB-expressing MDA-MB-468 xenografts had a mean SUV of 2.9,
while significantly lower in gpNMB-negative MDA-MB-231 tumors with a mean SUV
of 1.9. [89Zr]DFO-CR011 was also evaluated in patient-derived xenograft models of
TNBC, where tumor uptake in vivo had a positive correlation with total gpNMB protein
expression via ELISA (r = 0.79), despite the heterogeneity of gpNMB expression
within the same group of PDX mice. Lastly, the radiation dosimetry calculated from
biodistribution studies in MDA-MB-468 xenografts determined the effective dose for
human use would be 0.54 mSv/MBq. Overall, these studies demonstrate that [89Zr]
DFO-CR011 is a potential companion diagnostic imaging agent for CDX-011 which
targets gpNMB, an emerging biomarker for TNBC.
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INTRODUCTION

malignancies [12–14]. gpNMB is expressed in ≥ 25% of
tumor epithelial cells in about 40% of TNBC patients [9].
In most normal cells, gpNMB is expressed intracellularly,
which permits greater selectivity for targeting malignant
cells via the extracellular domain of this protein [15].
gpNMB is most commonly expressed in the basallike subtype of TNBC and has been found to promote
metastasis and is linked to recurrence [12, 13]. Higher
levels of gpNMB expression in TNBC are associated
with worse metastasis-free survival and overall survival
(OS). Preclinical studies in melanoma have shown that
the level of gpNMB expression is proportional to the
effectiveness of gpNMB-targeted therapy via an ADC
called glembatumumab vedotin (CDX-011) [16, 17].
Previous clinical trials have demonstrated an
acceptable safety profile of CDX-011 and improved
progression-free survival (PFS) of patients with gpNMBpositive breast cancer regardless of their subtype [9, 18].
In these studies, the greatest impact (objective response
rate (ORR), PFS, and OS) of CDX-011 relative to the
control arm was observed in patients with TNBC that
expressed gpNMB. In the EMERGE trial, increasing
levels of gpNMB expression (≥ 5% vs ≥ 25% positivity)
are associated with higher response rates (15% vs 30%,
respectively) to CDX-011 [9]. The efficacy of CDX-011
is being compared to capecitabine in the ongoing phase II
METRIC trial in patients with TNBC positive for gpNMB
in >25% of tumor epithelium by IHC of an archival tumor
material (NCT#01997333)[19]. Imaging gpNMB will
provide a non-invasive means for identifying patients
who may benefit from treatment with CDX-011. Taken
together, the expression of gpNMB plays an important role
in clinical outcome, making gpNMB an attractive target
for imaging and therapy of TNBC.
In this report, we describe the development of a
companion diagnostic imaging agent to image gpNMB in
xenograft models of TNBC. Our approach is to radiolabel
the naked antibody, glembatumumab (CR011), with a
PET radionuclide, Zr-89 (t1/2 = 3.3 days). The sensitivity
of PET combined with the decay properties of Zr-89
could be advantageous in providing high resolution
images and quantitative value in tracking the distribution
of the antibody in vivo well into its clearance from the
bloodstream [16]. Therefore, [89Zr]DFO-CR011 will
provide a non-invasive, quantitative, and sensitive
assessment of gpNMB expression in preclinical models
of TNBC and eventually in clinical trials. In this work,
we show the development of [89Zr]DFO-CR011 as a
companion diagnostic imaging agent via preclinical
evaluation to pre-qualify this PET agent for translation to
clinical trial. Toward this end, we evaluated its specificity
for gpNMB, immunoreactivity, stability, imaging quality,
pharmacokinetic properties, and dosimetry; all of which
are required for an investigational new drug (IND)
application to the FDA.

The rise of companion diagnostic imaging agents,
which are molecular imaging agents that provide
information on the effective use of the corresponding
drugs, is changing the paradigm of screening for targeted
therapy in cancer. Companion diagnostics typically
make use of in vitro testing of biopsied tissues using
immunohistochemistry, fluorescence in situ hybridization,
enzyme-linked immunosorbent assays, quantitative
PCR, or DNA sequencing, among others [1]. While
important for diagnosis, these techniques do not provide
information on the location of therapeutic targets and the
delivery of the therapeutic agents throughout the body.
Nuclear imaging of the expression of therapeutic targets
has the potential to identify patients who may benefit
from such therapies while sparing patients unlikely to
respond to unnecessary treatments. Several examples
have demonstrated the potential of PET imaging using
89
Zr-labeled antibodies as companion diagnostic agents
to (i) assess receptor targets in vivo especially in the
metastatic setting, (ii) identify candidate patients for
targeted therapy, and (iii) determine the overall safety of
these imaging agents [2–4]. In breast cancer, [89Zr]DFOtrastuzumab is paving the way towards the selection of
the human epidermal growth factor receptor 2 (HER2)positive patients for therapeutic antibodies that target this
receptor. While this companion diagnostic imaging agent
shows promise in stratifying patients who may benefit
from the already established HER2-targeted therapies,
there is currently no such approach for patients with the
triple negative breast cancer (TNBC) subtype.
TNBC is diagnosed by the absence of three receptors
that can be targeted for therapy: HER2, estrogen receptor,
and progesterone receptor. The current standard of care
for patients diagnosed with TNBC is chemotherapy, but
resistance to these treatments and early recurrence of
disease are prevalent [5, 6]. TNBC patients are also more
likely to develop metastases in the brain, bone, lung, and
liver [7]. For these reasons, TNBC is more aggressive
than other subtypes of breast cancer. However, targeted
treatments in clinical trials are currently gaining traction
to improve patient outcomes such as immune therapy and
antibody drug conjugates (ADCs) [8, 9]. In general, ADCs
deliver the drug payload specifically to cancer cells by
binding to receptors that are overexpressed on the cancer
cell surface, are internalized by the cell, and release the
drug to kill the cell via different mechanisms specific
for each type of ADC. ADCs have shown success in the
treatment of the HER2-positive breast cancer subtype [10,
11].
Using similar strategies to existing companion
diagnostic imaging agents for the HER2-positive breast
cancer subtype, we have developed a positron emission
tomography (PET) agent for imaging gpNMB. This
transmembrane glycoprotein is overexpressed in many
www.impactjournals.com/oncotarget
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RESULTS

serum, [89Zr]DFO-CR011 was 97% monomer initially,
and decreased to 64, 59, and 57 % at 1, 5, and 7 days,
respectively (Supplementary Figure 3).
[89Zr]DFO-CR011 was then characterized using
various cell binding assays in vitro. Human TNBC cell
lines were confirmed for cell surface expression of
gpNMB using flow cytometry (Supplementary Figure
4) and quantified total gpNMB expression from whole
cell lysate using ELISA (Supplementary Table 1). MDAMB-157, MDA-MB-468, and MDA-MB-231 were
determined to have high (11.1 ± 0.9 pg gpNMB/μg total
protein), moderate (2.7 ± 0.1), and negligible (0.15 ± 0.05)
expression of gpNMB, respectively (Supplementary Table
1), which is in agreement with the flow cytometry results
(Supplementary Figure 4). As a control, we used the
SK-Mel2 human melanoma cells, as this cell line highly
expresses gpNMB (6.8 ± 0.3) [17].
The immunoreactivity was determined using
a competitive binding assay, where the DFO-CR011
conjugate retained its antigen-binding property with a
2.2-fold ratio between EC50 values for DFO-CR011 (EC50
= 88 nM) and native CR011 (EC50 = 40 nM) (Figure
1A). Additionally, the binding affinity (Kd) of [89Zr]
DFO-CR011 and copy number of gpNMB (Bmax) were
determined via a radioligand saturation assay in SKMel2, MDA-MB-157, and MDA-MB-468, resulting

Characterization of [89Zr]DFO-CR011 in vitro
The ratio of DFO:CR011 was determined to be 4
(Supplementary Figure 1), which is comparable to that
of the drug:antibody ratio of 4 - 5 in CDX-011 [20–22].
The stability of [89Zr]DFO-CR011 was determined in
buffer at ambient temperature for 24 hrs, as this time point
under these conditions could be used to set an expiration
time for injection into patients from the end of antibody
radiolabeling. FPLC analysis showed the stability of
[89Zr]DFO-CR011 with a retention time of 22.5 min,
radiochemical purity of 100%, and antibody aggregation
of 7% at t0 and 10% at 24 hrs (Supplementary Figure 2).
This aggregation meets the specification of up to 20%
aggregation based on the criterion used for the chemistry,
manufacturing, and controls of an IND-approved [89Zr]trastuzumab, which means that an expiration time of 24
hrs can be used for injection into patients [23]. Further, a
serum stability study was performed in separate solutions
of human and mouse sera up to 7 days, in vitro. We found
that [89Zr]DFO-CR011 is more stable in human serum than
in mouse serum. In human serum, [89Zr]DFO-CR011 was
97% monomer initially, was maintained at 95% monomer
at 5 days, and decreased to 67% at 7 days. In mouse

Figure 1: Pharmacologic properties of [89Zr]DFO-CR011 in vitro. (A) Competitive binding study in MDA-MB-468. (B) Cell

uptake and blocking studies in cell lines with varying gpNMB expression. (C) The cell uptake of [89Zr]DFO-CR011 is correlated with
gpNMB expression in whole cell lysates (Pearson’s r = 0.95). (D) Rate of cellular internalization at 37ºC showed 50% of bound [89Zr]DFOCR011 internalized within 30 – 60 min. The reaction at 4ºC significantly reduced cellular internalization.
www.impactjournals.com/oncotarget
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Table 1: Biodistribution of [89Zr]DFO-CR011 in MDA-MB-468 xenografts under non-blocking and blocking
conditions from 1 – 12 days post injection (n = 3 per group)
Organ

1 day p.i. (%ID/g 1 day p.i. blocking 4 days p.i. (%ID/g 4 days p.i. blocking 7 days p.i. (%ID/g
± SD)
(%ID/g ± SD)
± SD)
(%ID/g ± SD)
± SD)

12 days p.i.
(%ID/g ± SD)

Blood

23.4

±

2.8

22.6

±

1.6

17.7

±

4.8

14.7

±

1.9

13.1

±

1.2

9.2

±

0.6

Lung

9.7

±

0.6

10.6

±

1.6

8.6

±

3.0

7.4

±

1.3

7.0

±

0.9

5.8

±

0.7

Liver

12.7

±

6.1

7.1

±

2.8

9.6

±

3.7

5.2

±

0.9

6.7

±

0.9

7.4

±

3.3

Spleen

5.6

±

1.0

6.9

±

1.1

7.8

±

3.4

6.5

±

2.2

7.4

±

1.3

7.7

±

1.5

Kidney

5.6

±

0.6

5.7

±

1.0

5.1

±

1.4

4.5

±

0.7

4.5

±

0.5

4.5

±

0.2

Muscle

3.0

±

0.6

2.9

±

0.3

2.3

±

0.7

2.2

±

0.3

2.0

±

0.4

1.7

±

0.1

Heart

8.3

±

2.4

6.9

±

0.9

5.9

±

2.3

4.6

±

1.1

5.1

±

0.5

2.9

±

0.1

Bone

2.4

±

0.2

2.2

±

0.3

5.4

±

1.9

4.3

±

0.6

6.7

±

0.8

10.3

±

2.1

Marrow

7.8

±

0.6

7.5

±

0.5

6.9

±

1.9

5.5

±

1.4

6.4

±

2.1

5.9

±

0.6

Tumor

13.3

±

1.9

11.0

±

2.2

22.1

±

2.0

10.0

±

2.0

24.5

±

7.7

23.5

±

2.9

Stomach

1.0

±

0.3

1.0

±

0.2

0.8

±

0.2

0.8

±

0.5

1.3

±

0.8

0.7

±

0.2

Values represent percent injected dose per gram ± standard deviation (%ID/g ± SD).

in an average Kd of 25 ± 5 nM in these cell lines
(Supplementary Figure 5A). This Kd value is in agreement
with previous studies reporting a Kd value of 52 nM for
native CR011 against recombinant gpNMB using nonradioactive methods [20]. Based on these saturation
assays, we interpolated Bmax values to determine the
number of gpNMB molecules per cell. We found that
there are about 605 ± 28 k gpNMB per MDA-MB-157
cell; 246 ± 5 k in MDA-MB-468; and 637 ± 12 k in SKMel2 (Supplementary Figure 5). Further, cell uptake
studies showed [89Zr]DFO-CR011 bound specifically
to MDA-MB-157 and MDA-MB-468 cells at 2 hrs of
incubation with 14 ± 1 and 3 ± 0.3 % bound/million cells,

respectively, and can delineate different expression levels
of gpNMB (Figure 1B). The high uptake in MDA-MB-157
was similar to that of the SK-Mel2 positive control with
13 ± 0.6 % bound/million cells. Blocking with excess
unlabeled CR011 significantly reduced [89Zr]DFO-CR011
uptake in MDA-MB-157, MDA-MB-468, and SK-Mel2
to 2 ± 0.6, 1 ± 0.2, and 0.8 ± 0.1 % bound/million cells,
respectively. As expected, the uptake in gpNMB-negative
MDA-MB-231 cells was minimal with 0.3 ± 0.03 %
bound/million cells. The cell uptake of [89Zr]DFO-CR011
in these cell lines was correlated with gpNMB expression
on whole cell lysates, as determined via ELISA. The

Figure 2: PET/CT imaging of [89Zr]DFO-CR011 in TNBC xenograft models at 4 days post-injection. (A) Maximum

Intensity Projections of representative mice. (B) Mean SUV in tumors at 4 and 7 days show significantly higher [89Zr]DFO-CR011 uptake
in MDA-MB-468 at both time points. (C) Biodistribution study post PET imaging at 7 days. Similar [89Zr]DFO-CR011 uptake in normal
organs were observed for both xenograft models.
www.impactjournals.com/oncotarget
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Pearson’s correlation coefficient was determined to be
0.95 (Figure 1C).
As the effectiveness of antibody drug conjugates
rely on the internalization of the antibody to the cell
to deliver the drug, we evaluated the rate of cellular
internalization of [89Zr]DFO-CR011 in MDA-MB-468
cells. We found that 50% of bound [89Zr]DFO-CR011 was
internalized within 30 – 60 min at 37°C, whereas [89Zr]
DFO-CR011 did not reach 50% internalization within
the 24-hr time point at 4°C (Figure 1D). Taken together,
these results show the feasibility of [89Zr]DFO-CR011 as
an excellent imaging agent for gpNMB. Its specificity,
high affinity, and rapid cellular internalization indicate
that [89Zr]DFO-CR011 could be an excellent companion
diagnostic agent for CDX-011 and a PET imaging agent
for gpNMB in vivo.

needed for future investigations to elucidate the cause of
decreased uptake of this radiotracer in these organs over
time. The biodistribution of this fully human [89Zr]DFOCR011 in normal organs of mice was consistent with
that of other 89Zr-labeled antibodies that are specific for
their human antigens [23, 24]. As expected, radioactive
uptake in the bone had a steady increase over the 12 days
from 2.4 ± 0.2 %ID/g at 1 day p.i. to 10.3 ± 2.1 %ID/g at
12 days p.i., which is likely due to the decomplexation
of Zr-89 from the antibody-DFO conjugate (Table 1)
[25]. Additionally, the specificity of [89Zr]DFO-CR011
was confirmed under blocking conditions from preadministration of 1 mg of unlabeled CR011 at 1 day prior
to the injection of [89Zr]DFO-CR011 in a subset of mice.
The tumor uptake of [89Zr]DFO-CR011 was reduced
by 50% at 4 days p.i. (Table 1). Based on these studies,
we performed PET imaging at 4 and 7 days p.i., where
optimal tumor-to-background (T/B) ratios were observed
in addition to maintaining imaging quality. PET imaging
of [89Zr]DFO-CR011 in MDA-MB-468 was compared to
that in the gpNMB-negative MDA-MB-231 xenograft.
Figure 2A shows maximum intensity projections of
MDA-MB-468 and MDA-MB-231, with higher tumor
uptake in the gpNMB-positive xenograft. Quantification
of tumor uptake at 4 and 7 days p.i. determined that [89Zr]
DFO-CR011 had a mean SUV of 2.9 ± 0.6 in the gpNMBpositive xenograft versus 1.6 ± 0.5 in the gpNMB-negative
model (P < 0.05) at 4 days p.i. (Figure 2B). The same
difference in uptake was observed at 7 days p.i. with a
mean of 2.9 ± 0.5 for MDA-MB-468, versus 1.4 ± 0.7
for MDA-MB-231 (P < 0.05). A post-PET biodistribution

[89Zr]DFO-CR011 is specific to gpNMB in cellderived xenograft models of TNBC
The pharmacokinetic properties were determined
via biodistribution studies at 1, 4, 7, and 12 days post
injection (p.i.) in MDA-MB-468 xenografts, where
the tumor uptake of [89Zr]DFO-CR011 increased from
13.3 ± 1.8 % ID/g at 1 day p.i. to 22.1 ± 2.0 % ID/g at
4 days p.i. (Table 1). The tumor uptake was constant
at 7 and 12 days p.i., with 24.5 ± 7.7 and 23.5 ± 2.9 %
ID/g, respectively, confirming the residualizing property
of Zr-89. The uptake in the blood, heart, and liver also
decreased, showing the slow clearance or metabolism
of [89Zr]DFO-CR011 over time. Metabolism studies are

Figure 3: Immunofluorescence staining of gpNMB in MDA-MB-468 (A) and MDA-MB-231 (B) tumor sections. Scale bars represent
50 μm. DAPI stained nuclei are marked blue and gpNMB stained (positive) membrane fragments are shown as green.
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Table 2: Residence times of [89Zr]DFO-CR011 in
MDA-MB-468 xenografts
Organ

Residence time, hrs

Blood

23.6 ± 3.4

Lungs

2.65 ± 0.41

Liver

5.54 ± 2.04

Spleen

0.45 ± 0.10

Kidneys

0.56 ± 0.07

Muscle

16.3 ± 3.3

Fat

9.4 ± 3.2

Heart

0.66 ± 0.15

Bone

7.68 ± 1.59

Red Marrow

3.61 ± 0.62

Pancreas

0.08 ± 0.01

Stomach

0.06 ± 0.02

Small Intestine

0.39 ± 0.07

Upper L. Intestine

0.11 ± 0.02

Lower L. Intestine

0.08 ± 0.02

Heart Content

2.36 ± 0.34

Remainder of the body

correspond to the 20, 10, and 2 μg of [89Zr]DFO-CR011,
respectively. Tumor:blood ratios for the 20 and 2 μg
doses were statistically significant (P = 0.03), which
could be due to a blocking effect. However, other dose
comparisons were not statistically significant (P > 0.05),
and could be due to shed antigen. While CR011 would
be able to bind to shed gpNMB, we did not test for the
presence of this shed antigen in our animal models due
to limited volume of blood samples. More investigations
are needed to determine the role of specific activity, mass
of antibody, and quantification of shed antigen in the
translation of [89Zr]DFO-CR011 to the clinical setting
in order to optimize the sensitivity of detecting gpNMB.
Nevertheless, [89Zr]DFO-CR011 can differentiate low
expression of gpNMB as compared with negative
expression in vivo (Figure 2B). Immunofluorescence
staining of gpNMB on these tumors ex vivo is consistent
with the imaging and biodistribution studies (Figure 3).
Raw data and H&E stains are shown in Supplementary
Figure 7. Despite the weak intensity of extracellular
gpNMB staining in the MDA-MB-468, PET using [89Zr]
DFO-CR011 was capable of detecting gpNMB in vivo.

Dosimetry of [89Zr]DFO-CR011 in MDA-MB-468
xenografts
Data from biodistribution studies were used to
determine radiation dosimetry. Organ residence times are
presented in Table 2. Due to the long circulation time of
antibodies, the blood residence times are observed to be the
highest with 23.6 hrs. The decay-corrected uptake in the
blood over time shows that the effective half-life of CR011
was about 8 days (Supplementary Figure 8A), which is
consistent with previous studies reporting a 10-day halflife using non-radioactive methods [20]. Blood-rich
organs such as liver and lungs also depict long residence
times. The rate of tumor uptake was also determined to
be 0.034% ID/g/hr, which corresponds to a half-life of 20
hrs (Supplementary Figure 8B). However, the long blood
residence time limits imaging at this earlier time point. The
organ and whole body radiation dosimetry is presented in
Table 3. The biodistribution, typical of antibodies, and the
long tracer retention time leads to an approximately 0.54
mSv/MBq dose in each organ. The heart appears to be the
dose-limiting organ due to the long retention in the blood.
A high radiation dose is also observed in the osteogenic
cells. The effective dose is measured at 0.54 mSv/MBq.
Under NRC CFR 361.1 regulation, these values indicate a
maximum recommended dose of 90 MBq (2.2 mCi) would
be feasible for patient studies.

72.5

study was performed to compare [89Zr]DFO-CR011 uptake
in normal organs and validate quantification from imaging
studies. No differences in organ uptake were observed for
these different models, with the exception of the tumor
(Figure 2C).
Interestingly, the tumor uptake in MDA-MB-468
from the biodistribution study following PET (post-PET
biodistribution) was about 50 % lower than that from the
biodistribution in the pharmacokinetic study at 7 days
p.i., with 11.9 ± 1.5 and 24.5 ± 7.7 % ID/g, respectively.
In the post-PET biodistribution study, we injected 20 μg
(3.7 MBq) of [89Zr]DFO-CR011 in order to obtain a high
imaging signal, compared with 10 μg (1.9 MBq) of [89Zr]
DFO-CR011 for the pharmacokinetic study. As the specific
activity is equivalent in both studies (185 MBq/mg), the
20 μg-injected dose in the post-PET biodistribution study
likely saturated gpNMB and, thus, yielded a lower % ID/g
at 7 days p.i. To test this hypothesis, we then conducted
a biodistribution study in a small subset of mice injected
with 2 μg (0.37 MBq) of [89Zr]DFO-CR011 at 7 days
p.i. to determine if a lower mass of antibody would
increase tumor uptake. We found no significant increase
in the tumor uptake for the 2 μg dose (20.4 ± 4.6 % ID/g)
compared with the 10 μg dose (Supplementary Figure 6).
Rather, we observed a trend of increasing tumor:blood
ratios with decreasing mass of antibody. Tumor:blood
ratios determined from biodistribution studies at 7 days
p.i. were 1.55 ± 0.05, 1.86 ± 0.22, and 1.92 ± 0.14 which
www.impactjournals.com/oncotarget
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Table 3: Predicted organ radiation doses for humans
Organ

Supplementary Figure 10 confirms the membrane and
cytoplasmic staining of gpNMB although quantification
using this technique was not performed due to the
heterogeneous expression of gpNMB within each PDX
tumor sample. Thus, we simplified our correlative analysis
to total gpNMB expression using ELISA. Despite the
heterogeneity of gpNMB expression, a positive correlation
was determined between [89Zr]DFO-CR011 tumor uptake
in vivo and total gpNMB expression ex vivo (r = 0.79,
Figure 4B).

(mSv/MBq)

Adrenals

0.67

Brain

0.49

Breasts

0.45

Gallbladder Wall

0.65

LL Intestine Wall

0.62

Small Intestine Wall

0.57

Stomach Wall

0.56

UL Intestine Wall

0.62

Heart Muscle

1.04

Kidneys

0.63

Liver

0.92

Lungs

0.71

Muscle

0.47

Ovaries

0.61

Pancreas

0.62

Red Marrow

0.63

Osteogenic Cells

1.04

Skin

0.37

Spleen

0.71

Thymus

0.60

Thyroid

0.49

Urinary

0.45

Uterus

0.62

Total

0.55

Effective Dose

0.54

DISCUSSION

(Supplementary Figure 9). WHIM-4 and WHIM5 models were selected for imaging studies, as these
PDX models expressed high and low mRNA levels
of gpNMB, respectively (Supplementary Figure 9).
Immunohistochemistry confirmed the relative protein
expression of gpNMB in earlier passages (A – D) of these
models that were available (Data not shown). PET using
[89Zr]DFO-CR011 was performed in passage E of WHIM4 and F of WHIM-5 at 4 and 7 days p.i., similarly to
imaging of MDA-MB-468 and MDA-MB-231 xenograft
models (Figure 4A). Total protein expression of gpNMB
was then confirmed following PET studies using ELISA
and IHC. This study shows that gpNMB expression was
heterogeneous in WHIM5F (n = 3) and lost expression in
WHIM4E (n = 5) (Figure 4A). Mean SUV of the [89Zr]
DFO-CR011 tumor uptake was correlated with total
gpNMB expression obtained from ELISA (Figure 4B).
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There is an unmet need to validate novel targets
for TNBC. The gpNMB is an example of an emerging
biomarker which is overexpressed in up to 40% of
TNBC. For this reason, the anti-gpNMB antibody drug
conjugate, CDX-011, has been accelerated into clinical
trials for the treatment of patients with advanced
TNBC, notably those who are refractory to standard
of care chemotherapy and demonstrated efficacy in
gpNMB over expressing tumors [9]. Incorporation
of companion diagnostic imaging agents in clinical
trials of CDX-011 could assist the selection of patient
candidates. Currently, gpNMB expression is determined
by IHC for patient eligibility. While IHC is a valuable
tool, a significant limitation is the sampling of a small
piece of the tumor often from an archival specimen
which may not be accurately representative of the
patients’ tumor lesion or distant lesions. In advanced
TNBC, the heterogeneity of gpNMB expression in
metastatic lesions is currently unknown. Further, IHC
cannot delineate membrane from cytoplasmic gpNMB
expression. PET imaging using [89Zr]DFO-CR011
could provide information about the heterogeneity of
gpNMB expression and quantify cell surface gpNMB,
a requirement for CDX-011 therapy. While tissue
distribution of the radiolabeled naked antibody may not
be exactly the same as that of the ADC, the affinity for
gpNMB is similar and is currently the best approach
for a companion diagnostic imaging agent despite this
inherent limitation. Additionally, shedding of gpNMB
extracellular domain via the ADAM10 sheddase activity
[26] might potentially render CDX-011 therapy less
effective. PET imaging using [89Zr]DFO-CR011 could
potentially predict the effectiveness of CDX-011.
In this study, we sought to evaluate [89Zr]DFOCR011 in preclinical models of TNBC to determine the
feasibility of this radiopharmaceutical for translation to
clinical trial as a companion diagnostic agent to CDX011. We chose Zr-89 over other radionuclides due to
its favorable half-life (3.3 days) that matches the 8-day
biological half-life of CR011 in mice (Supplementary
Figure 6B) to allow for imaging at later time points. Its
desired decay properties also permit high resolution
imaging, and its residualizing property could minimize
Oncotarget

the translocation of Zr-89 to other organs after cellular
internalization. Leveraging established chemistries and
the success of CDX-011 in Phase I/II clinical trials,
we applied [89Zr]DFO-CR011 PET in triple negative
breast cancer which currently lacks established targeted
treatments. Our work can serve as the basis to translate
[89Zr]DFO-CR011 to the clinic as a companion diagnostic
agent to CDX-011 with the potential to accelerate its
FDA-approval by providing a means to identify patients
who might benefit from this treatment strategy. Our
results show that [89Zr]DFO-CR011 binds specifically to
gpNMB and can distinguish different levels of cell surface
gpNMB expression based on our cell binding studies and
imaging in vivo (Table 1, Figures 1, 2, and 4). Despite the
heterogeneity observed in the clinically-relevant PDX
models, the sensitivity of detecting gpNMB in these
experiments and in the more established cell-derived
xenograft models shows that [89Zr]DFO-CR011 shows
promise in delineating the varying expression levels of
gpNMB in patients whose ability to respond to CDX-011
is dependent on the level of gpNMB expression [9]. Thus,
PET using [89Zr]DFO-CR011 has the potential to predict
response to CDX-011 in future investigations.
However, a limitation of this study is that we were
unable to assess the selectivity of [89Zr]DFO-CR011
for targeting gpNMB in the tumor versus gpNMB in

normal organs, as the CR011 antibody binds selectively
to human gpNMB. Despite this limitation, a dosimetry
study in mice is still required for clinical translation
to determine an estimated dose for human use (Table
3). PET imaging in humans would be a more accurate
way to assess the selectivity of [89Zr]DFO-CR011 for
gpNMB-overexpressing tumors over normal organs.
Thus, this concept warrants further investigation in a
clinical setting. Toward this goal, we prepared [89Zr]
DFO-CR011 similarly to other 89Zr-labeled antibodies
currently approved for clinical investigations [23, 27] to
estimate the radiation dosimetry for human use, which is
consistent with existing 89Zr-labeled antibodies that are
currently being investigated in clinical trials [23].
In conclusion, this work presents the first time
that gpNMB is imaged in vivo. PET imaging of
gpNMB using [89Zr]DFO-CR011 in these preclinical
studies demonstrates the feasibility of translating this
radiopharmaceutical to a clinical trial to select patients
with TNBC who might benefit from CDX-011. Further,
imaging gpNMB in the metastatic setting will determine
its overall expression throughout the body, and assess if
heterogeneity of gpNMB plays a role in patient outcome.
Lastly, PET imaging of gpNMB could be applied to other
cancer types that overexpress this clinically-relevant target
beyond triple negative breast cancer.

Figure 4: PET/CT imaging of [89Zr]DFO-CR011 in PDX models of TNBC at 7 days post-injection. (A) Maximum Intensity
Projections of WHIM-4E and WHIM-5F. Mean SUV are shown as values next to the tumors. (B) Correlative study between mean SUV in
the tumor and gpNMB expression via ELISA.
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MATERIALS AND METHODS

Characterization of the pharmacological
properties of [89Zr]DFO-CR011 in vitro

Cell lines and animal models

The specificity of [89Zr]DFO-CR011 was evaluated
in the TNBC cell lines which express high (MDAMB-157), moderate (MDA-MB-468), and negative
(MDA-MB-231) levels of gpNMB. SKMel-2 melanoma
cells were used as the positive control for gpNMB, as
this cell line has much higher gpNMB expression levels
than most breast cancer cell lines [12]. Each cell line
was seeded in 6-well plates in complete medium at 1 ×
105cells per well. The medium was changed to 1 mL of
starvation medium (1% FBS) and incubated for 24 hrs. All
cell studies described in this work were conducted under
these conditions. The medium was changed to 1 mL of 50
ng/mL of [89Zr]DFO-CR011 (9.25 kBq) in complete media
and was incubated for 2 hrs at 37ºC. Under blocking
conditions, a final concentration of 5 μg/mL of unlabeled
CR011 was added to the wells prior to the addition of
[89Zr]DFO-CR011. Cells were washed with 1 mL of PBS,
3×. Cells were harvested and assayed using an automatic
gamma counter (Perkin Elmer), from which the percentage
of cell-bound radiotracer was calculated and normalized to
the number of cells.
The immunoreactivity of [89Zr]DFO-CR011 was
determined using a competitive binding assay to compare
the ability of unlabeled native CR011 and DFO-CR011
conjugate to compete for binding to gpNMB with [89Zr]
DFO-CR011. MDA-MB-468 cells (500 μL of 5 × 105
cells/mL) were seeded in 12-well plates exposed to
varying concentrations of each competitor, native CR011
or DFO-CR011, ranging from 0 – 25 μg/mL (3-fold
dilutions) followed by a final concentration of 0.25 μg/
mL of [89Zr]DFO-CR011. The reaction was incubated
overnight. Cells were washed with PBS, harvested, and
assayed in a gamma counter as described above. The
percentage of bound radiotracer (B) was normalized to the
control reaction where no competitor was added (B0). B/B0
× 100 was plotted against the log concentration of added
competitor. Immunoreactivity was determined to be the
ratio between the effective concentrations at 50% (EC50)
binding between DFO-CR011 and CR011.
The rate of cellular internalization was determined
by incubating 250 μL of 50 ng/mL of [89Zr]DFO-CR011
with immobilized MDA-MB-468 cells at 37°C from 10
min to 24 hrs. The control reaction was performed at
4°C to show reduced internalization at this temperature.
Previous methods were followed for this procedure [31].

The human TNBC cell lines (MDA-MB-157, MDAMB-468 and MDA-MB-231) and the human melanoma
cell line (SK-Mel2) were obtained from the American
Type Culture Collection (ATCC) and were tested for
mycoplasma. These cells were cultured using Iscove’s
modified dulbecco’s medium (IMDM) supplemented with
10% fetal bovine serum (FBS) and 10μg/mL gentamycin
(complete medium) at 37ºC under humidified atmosphere
with 5% CO2. All cell lines were passaged < 40 times
prior to experiments. At the conclusion of this study, all
cell lines were authenticated using Illumina sequencing
and STARS analysis [28]. All cell studies were conducted
using these conditions unless stated otherwise.
All animal studies were conducted in compliance
with the Washington University Institutional Animal Care
and Use Committee. Female NCI athymic NCr-nu/nu
(5 – 7 weeks old) were obtained from Charles River and
1.5% isoflurane was used as anesthesia. Xenografts were
generated by inoculating the mice with 100 μL of ~107 cells
suspended in PBS, subcutaneously. Tumor sizes reached
between 100 - 500 mm3 at 4 weeks post inoculation for
MDA-MB-468 xenografts and 200 – 500 mm3 for MDAMB-231 at 2 weeks post inoculation. In our hands, MDAMB-157 cells did not form tumors in this strain of mice and
were only used for cell binding studies. PDX models were
obtained from the HAMLET Core facility [29].

Preparation of [89Zr]DFO-CR011
CR011 (Celldex Therapeutics) was conjugated via
lysine residues to desferrioxamine-p-benzyl-isothiocyanate
(Macrocyclics, Inc.) metal chelate (DFO-Bz-NCS) with
minor modifications from previous studies [23]. The
conjugation buffer used in the current study was PBS (pH
9) and the radiolabeling buffer was 10 mM sodium citrate
buffer (pH 6.8) to reduce antibody aggregation. Zr-89 was
produced in house with an effective specific activity of
145 – 656 mCi/μmol. The highest specific activity of [89Zr]
DFO-CR011 was achieved at 370 MBq/mg. The ratio of
DFO:CR011 was determined using a radioisotopic dilution
assay as described previously [30], except that FeCl3 was
used to compete with Zr-89. For cell-binding and animal
studies, a specific activity of 185 MBq/mg was prepared
to ensure ≥ 95% radiochemical yield. [89Zr]DFO-CR011
was purified by buffer exchanging with 2 mM sodium
citrate in saline. Protein aggregation was determined via
size exclusion chromatography (Superose 12 10/300 GL)
with a flow rate of 0.8 mL/min of 0.1 M sodium phosphate
(pH 6.5) containing 0.15 M NaCl buffer. An AKTA fast
protein liquid chromatography (FPLC) equipped with
radioactivity (Lablogic) and UV (A280nm) detectors was
used.
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Biodistribution, dosimetry, and PET imaging
studies
The pharmacokinetic properties of [89Zr]
DFO-CR011 were first determined by conducting a
biodistribution study in animals bearing MDA-MB-468
tumors. [89Zr]DFO-CR011 with a specific activity of 185
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Oncotarget

MBq/mg (100 μL of 1.85 MBq) was injected via tail vein
of the mice. Animals were euthanized at 1, 4, 7, and 12
days post injection (n = 3 per time point). Animals in the
blocking study group (n = 3) received 100-fold excess
(1 mg) of unlabeled CR011, 1 day prior to injection of
the radiolabeled antibody, and were euthanized at 1 and
4 days post injection of [89Zr]DFO-CR011. Animals were
grouped randomly for these experiments. Organs were
harvested, weighed, and assayed in a gamma counter, from
which the percentage of injected dose per gram of organ
(%ID/g) were calculated. T/B ratios were also calculated
to determine the optimal PET time points.
Organ biodistribution data were integrated to
generate the organ residence times. These residence times
were then scaled to human organ weight and entered
in OLINDA/EXM to generate human radiation dose
estimates using the adult human female model and using
the standard organ weight of ICRP 106 [32, 33]. Heart
content was assigned 10% of the blood residence time
and all unaccounted residence times was assigned to the
remainder of the body.
For small animal PET imaging, 3.7 MBq of [89Zr]
DFO-CR011 (specific activity = 185 MBq/mg) was
injected via tail vein. Static PET images were acquired
for 20 min. using an Inveon PET/CT scanner (Siemens,
Knoxville, TN) at 4 and 7 days post injection (p.i.). Images
were reconstructed using maximum a posteriori algorithm
and co-registered with CT images using Inveon Research
Workplace Workstation software (Siemens). The [89Zr]
DFO-CR011 tumor uptake was quantified by drawing
regions of interest on the tumor using CT as a guide. The
measured radioactivity was decay-corrected to the time of
injection of [89Zr]DFO-CR011 and the mean standardized
uptake values (SUV) were calculated.

with 2 variables. P < 0.05 was considered statistically
significant.

Immunofluorescence
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